Restoring Disc Health with Regenerative Medicine
Disc-mediated low back pain is one of the most common and most undertreated conditions in spine medicine. For patients who have exhausted conservative care and are not ready for — or interested in — surgery, the question becomes what comes next. Intradiscal regenerative medicine — including platelet-rich plasma and, in select cases, bone marrow aspirate concentrate — represents one of the most promising answers currently available, and when performed with the right preparation, the right technique, and the right patient selection, the evidence supports its ability to provide meaningful and durable relief.
THE BASICS
What Is Intradiscal PRP and How Does It Work?
Platelet-rich plasma is derived from your own blood, processed to separate and concentrate the platelets that carry the growth factors responsible for initiating tissue repair. In the intradiscal application, this concentrated solution — prepared at high concentration, typically ten times the body's baseline platelet count, and enriched with leukocytes to optimize the regenerative signal — is injected directly into the painful, degenerated disc under live fluoroscopic guidance. The goal is not to mask pain but to engage the disc's own repair biology. The intervertebral disc is a notoriously avascular structure with limited capacity for spontaneous healing, and the delivery of concentrated growth factors directly into that environment is designed to stimulate the cellular activity that the disc cannot reliably generate on its own. Research including work from the Hospital for Special Surgery has demonstrated meaningful improvement in pain and function within eight weeks of treatment, with many patients maintaining those benefits for a year or longer.
For patients with more advanced disc degeneration where PRP alone may provide insufficient regenerative stimulus, bone marrow aspirate concentrate — BMAC — represents a more potent biological option. BMAC is harvested from the patient's own iliac crest through a minimally invasive aspiration procedure, then processed to concentrate mesenchymal progenitor cells alongside a rich milieu of growth factors and bioactive proteins. Delivered intradiscally under the same image-guided technique, BMAC provides a richer cellular environment designed to drive a more robust regenerative response in discs where the degenerative cascade is more advanced. Like PRP, BMAC is entirely autologous — derived from the patient's own biology — which eliminates concerns about rejection or foreign material response. The selection between PRP and BMAC is determined by the degree of disc degeneration, the patient's clinical picture, and a careful assessment of what the biology of the individual disc is likely to respond to.
KEY DISTINCTION
Why Technique Is Not Incidental — It Is the Procedure
The biological quality of the regenerative preparation at the time of delivery determines the outcome as much as any other variable, and protecting that quality requires deliberate choices at every step of the procedure. I perform intradiscal PRP and BMAC using a two-needle technique under strict sterile conditions in an operating room setting, which minimizes contamination risk and reflects the standard of care these procedures warrant. No anesthetics are injected into the disc itself, as local anesthetics are cytotoxic to the cellular components that make both PRP and BMAC effective. No intradiscal antibiotics are mixed with either preparation, as these agents dilute and damage the regenerative components. Instead, intravenous antibiotics are administered beforehand to reduce infection risk safely without compromising the biologic. Every procedural decision — from blood or bone marrow processing to needle technique to the absence of disc-toxic additives — is made in service of preserving the integrity of what is being delivered. This is not a standardized injection. It is a precision biologic procedure, and it should be treated as one.
CLINICAL EVIDENCE
What Does the Research Show?
The evidence for intradiscal PRP has matured considerably over the past decade. Clinical studies consistently demonstrate that regenerative PRP therapies outperform corticosteroid injections beyond the three-month mark — a finding that reflects the fundamental difference between an anti-inflammatory strategy and a regenerative one. Steroid injections suppress the pain signal transiently; intradiscal PRP is designed to support structural improvement and sustained recovery of function. Prospective studies and registry data show statistically significant reductions in pain scores and improvements in functional indices at eight weeks, with durability extending to one year and beyond in a meaningful proportion of treated patients. The evidence supports the use of leukocyte-rich, high-concentration preparations specifically — formulation details that are not incidental but are directly linked to the biological activity driving clinical outcomes. The evidence base for intradiscal BMAC, while earlier in its development than PRP, supports its use in more advanced degenerative disc disease where the cellular environment of the disc requires a more potent regenerative stimulus than growth factors alone can provide. Centeno et al. and subsequent registry data have demonstrated safety and preliminary efficacy for bone marrow concentrate in disc applications, and the biological rationale — delivering living progenitor cells capable of differentiating toward disc cell phenotypes alongside concentrated growth factors — represents a meaningful step beyond what acellular preparations can achieve.
PATIENT SELECTION
Who Is a Good Candidate?
Intradiscal regenerative therapy is indicated for patients with chronic discogenic low back pain that has persisted despite at least six months of appropriate conservative care including physical therapy, activity modification, and oral medications. Before any regenerative procedure is recommended, I perform a complete history, physical examination, and thorough imaging review. Other pain generators — including facet joints, sacroiliac joints, and nerve root pathology — must be identified and either treated or excluded before discogenic pain is attributed as the primary driver. Diagnostic precision at this stage is not optional. Treating the wrong pain generator with any intervention, regenerative or otherwise, produces poor outcomes. Only patients with confirmed chronic discogenic pain as the primary clinical problem are candidates for these procedures. The choice between PRP and BMAC is individualized — patients with earlier-stage degeneration and a well-preserved disc architecture are typically excellent PRP candidates, while those with more advanced degenerative changes and a greater biological repair burden may benefit from the richer cellular content that BMAC provides.
The procedure is performed on an outpatient basis in an operating room setting. Most patients are advised to rest for approximately two weeks following treatment. A light brace may be used for two days to two weeks depending on activity level and comfort. Because leukocyte-rich PRP and BMAC are both designed to stimulate a controlled inflammatory healing response, some patients experience a temporary pain flare lasting up to 72 hours post-procedure. Oral pain medication may be used for comfort during this period. Anti-inflammatory medications including NSAIDs should be avoided, as they directly antagonize the healing response that the procedure is designed to initiate.
FOR REFERRING CLINICIANS
Intradiscal PRP and BMAC represent meaningful options for patients with chronic discogenic low back pain who have failed conservative management and are seeking an alternative to surgery or long-term medication dependence. Appropriate referral candidates include patients with MRI findings consistent with degenerative disc disease, concordant pain on clinical examination, and no evidence of progressive neurological compromise requiring surgical decompression. I perform a comprehensive pre-procedural evaluation including diagnostic workup to confirm discogenic pain as the primary generator, individualize the regenerative approach between PRP and BMAC based on the degree of degeneration and clinical picture, and provide detailed documentation of findings, technique, and follow-up plan back to the referring provider. No injection or biologic procedure exists in isolation in my practice — it is part of a comprehensive plan that includes rehabilitation and ongoing functional optimization. I welcome direct physician-to-physician consultation.
PERSPECTIVE
A Note on Regenerative Medicine Done Deliberately
Regenerative medicine has generated both genuine excitement and significant noise over the past decade, and not all of it has been warranted. Platelet-rich plasma has been applied to conditions where the evidence is weak, using preparations that are inconsistent, and with techniques that undermine the biology the therapy depends on. BMAC has similarly been oversold in contexts where the evidence does not yet support it and undersold in contexts where it offers a meaningful advantage over acellular alternatives. I have no interest in either version of that story. What I am interested in is applying these technologies precisely — to the right diagnosis, with the right preparation, using the right technique — in a way that gives the biology a genuine opportunity to work. For patients with chronic discogenic pain who have exhausted conservative options and are not ready for surgery, that opportunity is real. The disc is not an easy structure to treat. But it is not untreatable, and for the right patient, intradiscal regenerative therapy represents one of the most meaningful nonoperative options currently available in spine care.
DISCLOSURE & REFERENCES
This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Levi D et al. 2016 (intradiscal PRP, Pain Med); Akeda K et al. 2017 (PRP for disc degeneration, Spine J); Tuakli-Wosornu YA et al. 2016 (HSS intradiscal PRP RCT, PM&R); Obata S et al. 2012 (anesthetic cytotoxicity to disc cells, Spine); Patel VB et al. 2018 (leukocyte-rich PRP formulation and outcomes); Centeno CJ et al. 2017 (bone marrow concentrate for disc and spine applications, Pain Physician).
ABOUT THE AUTHOR
Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.
